Drug combinations that target particular cancer mutations will be tested by ComboMATCH.
National Human Genome Research Institute is credited.
In order to evaluate the efficacy of treating adults and children with novel drug combinations that target particular tumor alterations, the National Cancer Institute( NCI) has launched a sizable precision medicine cancer initiative. The largest program of its kind to test combinations of cancer medications guided by tumor biology is called the Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice ( ComboMATCH ). The goal of the project is to find effective therapies that can advance to larger, more conclusive clinical trials outside of ComboMATCH. The National Institutes of Health includes NCI.
Numerous phase 2 treatment trials make up ComboMATCH, which will each assess a drug combination, typically two targeted drugs or one targeted drug plus chemotherapy. Patients with specific changes in their cancer cells will be included in